Surgical Science Sweden Dirección
Dirección controles de criterios 4/4
El CEO de Surgical Science Sweden's es Gisli Hennermark , nombrado en Sep 2015, tiene una permanencia de 8.58 años. compensación anual total es SEK5.83M, compuesta por 73.7% salario y 26.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.67% de las acciones de la empresa, por valor de SEK51.74M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 5.1 años, respectivamente.
Información clave
Gisli Hennermark
Chief Executive Officer (CEO)
kr5.8m
Compensación total
| Porcentaje del salario del CEO | 73.7% |
| Permanencia del CEO | 8.7yrs |
| Participación del CEO | 0.7% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 5.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Earnings Beat: Surgical Science Sweden AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 21
Here's Why Surgical Science Sweden (STO:SUS) Has Caught The Eye Of Investors
Apr 16Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Mar 17Results: Surgical Science Sweden AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Feb 24Is There Now An Opportunity In Surgical Science Sweden AB (publ) (STO:SUS)?
Nov 29Should You Be Adding Surgical Science Sweden (STO:SUS) To Your Watchlist Today?
Oct 07Is Surgical Science Sweden AB (publ) (STO:SUS) Trading At A 39% Discount?
Aug 17With EPS Growth And More, Surgical Science Sweden (STO:SUS) Makes An Interesting Case
Jun 20A Look At The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
May 17Surgical Science Sweden AB (publ) (STO:SUS) Shares Could Be 49% Below Their Intrinsic Value Estimate
Dec 27Is Now The Time To Put Surgical Science Sweden (STO:SUS) On Your Watchlist?
Dec 06Is Now The Time To Look At Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Sep 08We Ran A Stock Scan For Earnings Growth And Surgical Science Sweden (STO:SUS) Passed With Ease
Aug 23Surgical Science Sweden AB (publ) (STO:SUS) Shares Slammed 33% But Getting In Cheap Might Be Difficult Regardless
May 26Here's Why We Think Surgical Science Sweden (STO:SUS) Is Well Worth Watching
Apr 29An Intrinsic Calculation For Surgical Science Sweden AB (publ) (STO:SUS) Suggests It's 44% Undervalued
Feb 20Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jan 11Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Dec 15Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Sep 16Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Jul 05Calculating The Fair Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Jun 08Is It Too Late To Consider Buying Surgical Science Sweden AB (publ) (STO:SUS)?
Mar 23Calculating The Intrinsic Value Of Surgical Science Sweden AB (publ) (STO:SUS)
Mar 02Is Surgical Science Sweden AB (publ)'s (STO:SUS) Shareholder Ownership Skewed Towards Insiders?
Feb 09
Surgical Science Sweden AB (publ)'s (STO:SUS) Stock Is Going Strong: Have Financials A Role To Play?
Jan 01What Does Surgical Science Sweden AB (publ)'s (STO:SUS) Share Price Indicate?
Dec 14Does Surgical Science Sweden (STO:SUS) Deserve A Spot On Your Watchlist?
Nov 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | kr208m |
| Dec 31 2023 | kr6m | kr4m | kr234m |
| Sep 30 2023 | n/a | n/a | kr253m |
| Jun 30 2023 | n/a | n/a | kr234m |
| Mar 31 2023 | n/a | n/a | kr221m |
| Dec 31 2022 | kr5m | kr4m | kr188m |
| Sep 30 2022 | n/a | n/a | kr138m |
| Jun 30 2022 | n/a | n/a | kr124m |
| Mar 31 2022 | n/a | n/a | kr101m |
| Dec 31 2021 | kr4m | kr3m | kr86m |
Compensación vs. Mercado: La compensación total de Gisli($USD541.19K) está por debajo de la media de empresas de tamaño similar en el mercado Swedish ($USD812.32K).
Compensación vs. Ingresos: La compensación de Gisli ha sido consistente con los resultados de la empresa en el último año.
CEO
Gisli Hennermark (51 yo)
8.7yrs
Permanencia
kr5,826,000
Compensación
Mr. Gisli Hennermark serves as Chief Executive Officer of Surgical Science Sweden AB (publ) since September 2015. He serves as board member of Panasari AB and Espansari AB. He worked previously as a manage...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chief Executive Officer | 8.7yrs | kr5.83m | 0.67% SEK 47.4m | |
| Co-Founder & CTO | 5.3yrs | sin datos | 0.059% SEK 4.2m | |
| Chief Financial Officer | 6.3yrs | sin datos | 0.047% SEK 3.3m | |
| Chief Operating Officer | 3.3yrs | sin datos | 0.036% SEK 2.6m | |
| Head of Global Sales | 3.3yrs | sin datos | sin datos | |
| Executive Vice President of Products & Marketing | 2.5yrs | sin datos | 0.036% SEK 2.6m | |
| Head of Development | 4.5yrs | sin datos | sin datos | |
| Chief Innovation Officer | 3.3yrs | sin datos | sin datos | |
| President of Research & Development | 2.3yrs | sin datos | 0.042% SEK 3.0m | |
| Executive Vice President of International Sales & Educational Products | no data | sin datos | 0.010% SEK 713.1k | |
| Executive Vice President of Industry & OEM | 2yrs | sin datos | sin datos |
3.3yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de SUS se considera experimentado (3.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 19.3yrs | sin datos | 11.74% SEK 829.9m | |
| Director | 19.3yrs | sin datos | 13.99% SEK 988.7m | |
| Independent Director | 7.3yrs | sin datos | 0.0020% SEK 138.5k | |
| Independent Director | less than a year | sin datos | 0.00069% SEK 48.8k | |
| Independent Director | 3yrs | sin datos | 0.0026% SEK 180.2k | |
| Independent Director | 3yrs | sin datos | 0.0020% SEK 138.5k |
5.2yrs
Permanencia media
53.5yo
Promedio de edad
Junta con experiencia: La junta directiva de SUS se considera experimentada (5.1 años de antigüedad promedio).